-
Johnson & Johnson Announces First Quarter Results Report Increased by 7.9% Year-on-year
Time of Update: 2021-07-08
After excluding the net impact of acquisitions, divestitures, and exchange rate conversions, based on business operations, global sales increased by 3.
Among them, a number of drugs in the immunology business performed strongly, including Stelara (increased by 9.
-
Chuangsheng Group announced that its new anti-PD-L1 and TGF-β bifunctional antibody drug TST005 has been approved by the U.S. FDA for clinical trials
Time of Update: 2021-07-08
"TST005 is one of the few leading drug candidates targeting PD-L1/TGF-β dual-functional antibodies currently under clinical development in the world .
-
To help the Beijing medical team's aid to Tibet, Wolters Kluwer Group UpToDate entered Lhasa People's Hospital
Time of Update: 2021-07-08
On April 12, Professor Peng Xiaoxia held an academic report in the conference hall of the outpatient building of Lhasa People's Hospital, and customized two academic lectures for the hospital, namely "UpToDate supports clinical decision-making and clinical research" and "Clinical research topic selection" .
-
Sanofi considers selling the nutrition and vitamin business of its Indian branch
Time of Update: 2021-07-08
On April 26, there were media reports that according to people familiar with the matter, Sanofi India is conducting in-depth negotiations on the sale of part of its over-the-counter drug business .
A spokesperson for Piramal declined to comment, and Sanofi and Dr.
Reddy's laboratories also declined to comment .
-
Shihe Gene and AstraZeneca Strategic Cooperation: Co-build Guangzhou Biodiagnosis Innovation Center to Deploy Tumor Full Cycle Management
Time of Update: 2021-07-08
Through the strategic cooperation between the two parties, S&Gene's technological research and development advantages in the field of precision medical diagnosis and AstraZeneca in tumor, respiratory Diseases and other fields are fully integrated from the complete "patient-centered" innovative diagnosis and treatment integration program of disease diagnosis, treatment and rehabilitation, and strengthen cooperation in the development of precision diagnostic products .
-
Online prescription drugs are coming, but Tai'antang sold this well-known medical e-commerce company
Time of Update: 2021-07-08
After the transaction is completed, the listed company will divest its original pharmaceutical e-commerce business, and focus its resources on the main businesses such as the research and development, manufacturing and sales of Chinese patent medicines, and the initial processing and sales of Chinese medicinal materials .
-
To reduce the disability rate of children with hemophilia, the first domestic long-acting recombinant blood coagulation nine-factor new drug, Sai Jiu Ning, was approved
Time of Update: 2021-07-08
Sanofi announced today that China's National Medical Products Administration has approved Ainocoagulin α for injection (ie, recombinant human coagulation factor IX-Fc fusion protein for injection, trade name: Saijiu Ning®, English trade name Alprolix®) for diagnosis For adults and children with hemophilia B (congenital factor IX deficiency), bleeding control, routine prevention, and perioperative bleeding management .
-
Fujifilm Irwin Technology attended the 4th China Medical Industry Innovation and Development Conference
Time of Update: 2021-07-08
In recent years, the Fujifilm Group has made medical and health one of the key development areas of the company, combining its core technologies accumulated in film production with new technologies s
-
"Advertising King" Harbin Pharmaceutical, what is the status of other established pharmaceutical companies who love to smash advertisements?
Time of Update: 2021-07-08
However, under the huge loss, the high salary of its directors and supervisors not only did not decrease, but also increased substantially: The financial report shows that during the period 2018-2020, the total pre-tax remuneration received by the management of Harbin Pharmaceuticals was 9.
-
Experts from the International Cancer Center of the International Cancer Center talk about clinical problems
Time of Update: 2021-07-08
At Jiahui International Cancer Center, doctors can fully understand and communicate with patients' actual conditions, so that patients and their families can more clearly understand the purpose of NGS sequencing, so as to formulate the best diagnosis and treatment plan .
-
Under the dazzling performance, Yuyue Medical's strong strength and hard logic
Time of Update: 2021-07-08
Macro-trends established corporate strength support The aging trend is accelerating, the base of patients with chronic diseases has expanded, and users' awareness of home monitoring has reached a preliminary stage of maturity after years of market education.
With the focus of R&D, market, and investment, there is still sufficient growth potential to be released .
-
Odivo became the world's first first-line immunotherapy drug for gastric cancer approved by regulatory agencies
Time of Update: 2021-07-08
"CheckMate-649 study results show that Odivo combined with chemotherapy can significantly improve the survival of patients with metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, and reduce the risk of death by 20% .
-
Russia Direct Investment Fund and Hualan Biotechnology reached an agreement
Time of Update: 2021-07-08
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) said:"The cooperation agreement with China's leading vaccine manufacturer Hualan Biovaccine Co.
The Russian Direct Investment Fund (RDIF) was established in 2011, mainly to make equity investments in Russian companies together with leading foreign financial and strategic investors .
-
New breakthroughs have been made in the secondary development of Banlangen of Guangzhou Pharmaceutical Group
Time of Update: 2021-07-08
In terms of industry influence, it can improve the quality of existing products; second, in terms of promoting industrial upgrading, it is expected to develop new Banlangen medicine; third, it will help the development of Chinese medicine in the Greater Bay Area, will accelerate the transformation of scientific research results, and realize the registration and listing of Banlangen preparations in the Macao Special Administrative Region.
-
Microchip's partner submits Chidamide's listing application in Japan and is accepted
Time of Update: 2021-07-07
Chidamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and the world's first oral administration approved for the treatment of peripheral T-cell lymphoma and combined with endocrine drugs for the treatment of estrogen receptor-positive breast cancer patients The drug, targeting class I histone deacetylase (HDAC), induces cell cycle arrest, inhibits the expression of a variety of oncogenes, regulates the acetylation of PD-L1, and enhances the activity of immune checkpoint inhibitors.
-
Boan Bio-Nivolumab Injection LY01015 was approved for clinical research
Time of Update: 2021-07-07
Luye Pharmaceutical Group announced that the nivolumab injection (LY01015) developed by its holding subsidiary Boan Biotechnology has been approved by the National Medical Products Administration for clinical research .
In terms of biosimilars, in addition to LY01015, LY01008 (Avastin® biosimilar) is expected to be approved for marketing in China soon.
-
The anti-epidemic hero assumed the new National Bureau of Disease Control and Prevention, and the adjustment of the disease control system "breaks"?
Time of Update: 2021-07-07
Its responsibilities are to formulate major disease prevention and control plans, national immunization plans, and intervention measures for public health problems that seriously endanger people’s health and organize their implementation, improve the disease prevention and control system, and undertake infections.
-
Essilor launches myopia management training certification project
Time of Update: 2021-07-07
To this end, Essilor Optics and AOMA Asia Eye Optometry Practicing Management Association have cooperated to launch the certification of youth myopia management training, aiming to meet the actual needs of consumers, through professional standards and authoritative guidance, in the "screening, testing, recommendation, matching The six dimensions of "school, school and maintenance" give consumers a more scientific fitting experience .
-
DiA and Kaili Medical jointly provide AI solutions for cardiac ultrasound
Time of Update: 2021-07-07
Hila Goldman-Aslan, CEO and co-founder of DiA Imaging Analysis, said: "We are very pleased to work with Kaili Medical to provide users with the most advanced AI ultrasound solutions .
-
China will join Galmed's Phase 3 ARMOR study on Aramchol's treatment of NASH and fibrosis
Time of Update: 2021-07-07
The company announced today that the National Medical Products Administration (NMPA) of China has approved Galmed's application for a new drug clinical trial application (IND) for the Phase 3 ARMOR study of Aramchol for the treatment of NASH and fibrosis .
